Literature DB >> 12707950

Different mutations in the NF1 gene are associated with Neurofibromatosis-Noonan syndrome (NFNS).

Diana Baralle1, Chris Mattocks, Kamini Kalidas, Frances Elmslie, Joanne Whittaker, Melissa Lees, Nicola Ragge, Michael A Patton, Robin M Winter, Charles ffrench-Constant.   

Abstract

The association of the Noonan phenotype with neurofibromatosis type 1 (NF1) was first noted by Allanson et al. [Am J Med Genet 1985;21:457-462.] and 30 further cases have subsequently been reported. It has been suggested that this phenotype is more common than previously appreciated, as Colley et al. [Clin Genet 1996;49:59-64.] examined 94 sequentially identified patients with NF1 from their genetic register and found Noonan features in 12. A 3-bp deletion of exon 17 of the NF1 neurofibromin gene was described in one family by Carey et al. [Proc Greenwood Genet Center 1997;17:52-53]. However, it remains unclear whether Neurofibromatosis-Noonan syndrome (NFNS) represents a form of NF1 (with mutations in the NF1 neurofibromin gene) or a separate syndrome. We have used a new, rapid sequence analysis technique-comparative sequence analysis (CSA)-to examine the NF1 gene in six patients with NFNS. None of the six patients had the previously identified mutation, nor did we observe other mutations within this exon. However, two other mutations were found: in exon 25, a 3-bp deletion 4312 del GAA, and in exon 23-2, a 2-bp insertion 4095 ins TG. The PTPN11 gene, now known to cause over 50% of Noonan syndrome was also examined in four cases of NFNS, and no mutations were found. These results show that NFNS can in some cases result from different mutations in the NF1 gene and therefore represents a variant form of NF1. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707950     DOI: 10.1002/ajmg.a.20023

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  17 in total

1.  Noonan syndrome: clinical aspects and molecular pathogenesis.

Authors:  M Tartaglia; G Zampino; B D Gelb
Journal:  Mol Syndromol       Date:  2010-01-15

2.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

3.  The neurofibromin GAP-related domain rescues endothelial but not neural crest development in Nf1 mice.

Authors:  Fraz A Ismat; Junwang Xu; Min Min Lu; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2006-08-10       Impact factor: 14.808

Review 4.  Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.

Authors:  Marco Tartaglia; Bruce D Gelb
Journal:  Ann N Y Acad Sci       Date:  2010-10-19       Impact factor: 5.691

5.  An absence of cutaneous neurofibromas associated with a 3-bp inframe deletion in exon 17 of the NF1 gene (c.2970-2972 delAAT): evidence of a clinically significant NF1 genotype-phenotype correlation.

Authors:  M Upadhyaya; S M Huson; M Davies; N Thomas; N Chuzhanova; S Giovannini; D G Evans; E Howard; B Kerr; S Griffiths; C Consoli; L Side; D Adams; M Pierpont; R Hachen; A Barnicoat; H Li; P Wallace; J P Van Biervliet; D Stevenson; D Viskochil; D Baralle; E Haan; V Riccardi; P Turnpenny; C Lazaro; L Messiaen
Journal:  Am J Hum Genet       Date:  2006-12-08       Impact factor: 11.025

Review 6.  Noonan syndrome and clinically related disorders.

Authors:  Marco Tartaglia; Bruce D Gelb; Martin Zenker
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-02       Impact factor: 4.690

7.  A new nonsense mutation in the NF1 gene with neurofibromatosis-Noonan syndrome phenotype.

Authors:  Sevgi Yimenicioğlu; Ayten Yakut; Kadri Karaer; Martin Zenker; Arzu Ekici; Kürşat Bora Carman
Journal:  Childs Nerv Syst       Date:  2012-09-11       Impact factor: 1.475

8.  Increased rate of missense/in-frame mutations in individuals with NF1-related pulmonary stenosis: a novel genotype-phenotype correlation.

Authors:  Shay Ben-Shachar; Shlomi Constantini; Hen Hallevi; Emma K Sach; Meena Upadhyaya; Gareth D Evans; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2012-10-10       Impact factor: 4.246

9.  Clinical and molecular aspects of an informative family with neurofibromatosis type 1 and Noonan phenotype.

Authors:  D A Stevenson; D H Viskochil; A F Rope; J C Carey
Journal:  Clin Genet       Date:  2006-03       Impact factor: 4.438

10.  Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype.

Authors:  Claudio Carta; Francesca Pantaleoni; Gianfranco Bocchinfuso; Lorenzo Stella; Isabella Vasta; Anna Sarkozy; Cristina Digilio; Antonio Palleschi; Antonio Pizzuti; Paola Grammatico; Giuseppe Zampino; Bruno Dallapiccola; Bruce D Gelb; Marco Tartaglia
Journal:  Am J Hum Genet       Date:  2006-05-01       Impact factor: 11.025

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.